{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:34:31Z","timestamp":1790087671165,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022336","name":"Esperion Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","ajconline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.amjcard.2016.03.043","type":"journal-article","created":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T03:45:47Z","timestamp":1459914347000},"page":"1928-1933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy"],"prefix":"10.1016","volume":"117","clinical-trial-number":[{"clinical-trial-number":"nct02072161","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christie M.","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"McKenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane E.","family":"MacDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice R.","family":"Margulies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula L.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Hanselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra D.","family":"Lalwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2016.03.043_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1042\/bj2720181","article-title":"The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2","volume":"272","author":"Berkhout","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/j.amjcard.2016.03.043_bib2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/MOL.0000000000000091","article-title":"LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase","volume":"25","author":"Filippov","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjcard.2016.03.043_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.amjcard.2016.03.043_bib4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"Ballantyne","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.03.043_bib5","doi-asserted-by":"crossref","unstructured":"Thompson PD, Ballantyne CM, McKenney JM, Orloff DG, MacDougall DE, Margulies JR, Hanselman JC, Newton RS. ETC-1002 lowers LDL-C more than ezetimibe in patients with hypercholesterolemia with or without statin intolerance and has a similar safety and tolerability profile. Poster Presented at: 64th Annual Meeting of the American College of Cardiology; March 2015; San Diego, CA.","DOI":"10.1016\/S0735-1097(15)61349-3"},{"key":"10.1016\/j.amjcard.2016.03.043_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2796.2006.01616.x","article-title":"Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person\/ten-country panel","volume":"259","author":"Barter","year":"2006","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.amjcard.2016.03.043_bib7","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/07853890801964955","article-title":"Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points Through Aggressive Lipid-lowering Trial (IDEAL)","volume":"40","author":"Holme","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.amjcard.2016.03.043_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.atherosclerosis.2014.05.914","article-title":"Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets","volume":"235","author":"Toth","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2016.03.043_bib9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCULATIONAHA.113.002671","article-title":"High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy","volume":"128","author":"Mora","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2016.03.043_bib10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","article-title":"Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus","volume":"34","author":"Gutierrez","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2016.03.043_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.amjcard.2016.03.043_bib12","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.03.043_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2016.03.043_bib14","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjcard.2016.03.043_bib15","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2016.03.043_bib16","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.03.043_bib17","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2016.03.043_bib18","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.03.043_bib19","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.03.043_bib20","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cjca.2015.03.019","article-title":"New hope for lipid-lowering beyond statins: effect of IMPROVE-IT on understanding and implementation of atherosclerosis prevention","volume":"31","author":"Anderson","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.amjcard.2016.03.043_bib21","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1093\/eurheartj\/eht213","article-title":"Beyond statins: what to expect from add-on lipid regulating therapy?","volume":"34","author":"Laufs","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2016.03.043_bib22","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.amjcard.2016.03.043_bib23","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMe1507041","article-title":"Proof that lower is better\u2014LDL cholesterol and IMPROVE-IT","volume":"372","author":"Jarcho","year":"2015","journal-title":"N\u00a0Engl J Med"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916304301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914916304301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T18:24:30Z","timestamp":1668623070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914916304301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0002914916304301"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.03.043","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2016.03.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}